Merck Forecasts Global Molnupiravir Revenues Of $5bn-$7bn Through 2022
Assuming emergency use authorization of the antiviral to fight COVID-19 in December, Merck expects to make $500m-$1bn this year. It will share profits equally with partner Ridgeback.
You may also be interested in...
The antiviral for COVID-19 added $952m to Merck's top line in 2021 and is forecast to deliver $5bn-$6bn in 2022, but CEO Davis sees potential for the product beyond the current pandemic, including potential combinations.
Merck and Lilly tackle some early challenges before striking voluntary licensing deals for COVID-19 therapies with Indian firms. Data around the use of these drugs in low- and middle-income countries could also potentially make them ‘more acceptable’ elsewhere, experts say.
India authorizes molnupiravir for restricted emergency use in COVID-19, marking the arrival of around a dozen “affordable” generics of Merck & Co. and Ridgeback Biotherapeutics' oral antiviral. Physicians say data are “pretty compelling” notwithstanding the narrow FDA nod.